Result of AGM

 

TIDMNWBS TIDMNWBT 
 
RNS Number : 5959Y 
Northwest Biotherapeutics Inc 
04 September 2009 
 

+-----------------------------------------+-----------------------------------------+ 
| For immediate release                   |                        4 September 2009 | 
+-----------------------------------------+-----------------------------------------+ 
 
 
Northwest Biotherapeutics, Inc. 
 
 
("NWBT", "Northwest" or the "Company") 
 
 
NORTHWEST BIOTHERAPEUTICS HOLDS ANNUAL GENERAL MEETING 
 
 
 
 
BETHESDA, MD -September 4, 2009 - Northwest Biotherapeutics, Inc. (AIM: NWBT and 
NWBS; OTCBB: NWBO) today announces that all resolutions put to the Company's 
shareholders at today's Annual General Meeting held today in Bethesda, MD, USA 
have been approved. The resolutions included: (1) the approval of Linda F. 
Powers as a Class Two Director; (2) the increase in the number of authorized 
shares in the Company from 100,000,000 to 150,000,000; and (3) the cancellation 
of the Company's listing on the London Stock Exchange's AIM market ("AIM"). The 
Company plans to continue its listing in the U.S., on the NASD Over the Counter 
Bulletin Board Market ("U.S. listing") and plans to file an S1 registration 
statement under which the Company's shares held on AIM may become tradable on 
the US market.  The trading of the Company's shares on AIM is expected to be 
cancelled on September 14, 2009. 
 
 
 
 
About Northwest Biotherapeutics 
 
Northwest Biotherapeutics is a biotechnology company focused on developing 
immunotherapy products that treat cancers more effectively than current 
treatments, without toxicity, on a cost-effective basis. The Company has two 
broad platform technologies: dendritic cell-based vaccines and therapeutic 
antibodies. The Company is in a large Phase II clinical trial in GBM, with 13 
clinical sites across the U.S. The Company has also received clearance from the 
FDA for a large Phase III trial in prostate cancer, and for Phase I trials in 
five other cancers. The Company has started, and is currently enrolling patients 
in, a Phase I/II trial with DCVax  for recurrent metastatic ovarian cancer. The 
Company's second technology platform, involving antibodies to CXCR4, is at the 
late pre-clinical development stage. 
 
 
For further information about clinical sites and Company information please 
visit the company web site at www.nwbio.com. 
 
 
 
 
Disclaimer 
 
 
Statements made in this news release that are not historical facts, including 
statements concerning future securities registrations or other filings with the 
U.S. Securities and Exchange Commission ("SEC"), future treatment of patients 
with GBM using DCVax -Brain, and other future clinical trials, are 
forward-looking statements within the meaning of the Private Securities 
Litigation Reform Act of 1995. Words such as "may," "expects," "believes," 
"intends," "anticipates," and similar expressions are intended to identify 
forward-looking statements. Actual results may differ materially from those 
projected in any forward-looking statement. Specifically, there are a number of 
important factors that could cause actual results to differ materially from 
those anticipated, such as the SEC's review and evaluation of securities 
registrations or other filings, the Company's ability to raise additional 
capital, risks related to the Company's ability to enroll patients in its 
clinical trials and complete the trials on a timely basis, uncertainties related 
to the clinical trials process, uncertainties about the timely performance of 
third parties, and uncertainties about whether the Company's products will 
demonstrate safety and efficacy. Additional information on these and other 
factors, which could affect the Company's results, is included in its SEC 
filings and the Risk Factors section of the Form S-1 that the Company is 
preparing to file. Finally, there may be other factors not mentioned above or 
included in the Company's SEC filings or upcoming Form S-1 that may cause actual 
results to differ materially from those projected in any forward-looking 
statement. You should not place undue reliance on any forward-looking 
statements. The Company assumes no obligation to update any forward-looking 
statements as a result of new information, future events or developments, except 
as required by securities laws. 
 
 
For further information, please contact: 
 
 
+----------------------------------------------------------------+----------------------+ 
| Northwest Biotherapeutics, Inc.                                |      [phone] | 
+----------------------------------------------------------------+----------------------+ 
| Alton L. Boynton, Chief Executive Officer                      |                      | 
+----------------------------------------------------------------+----------------------+ 
|                                                                |                      | 
+----------------------------------------------------------------+----------------------+ 
| Buchanan Communications                                        |  [phone] | 
+----------------------------------------------------------------+----------------------+ 
| Lisa Baderoon ([e-mail]) / Mary-Jane Johnson /    |                      | 
| Catherine Breen                                                |                      | 
+----------------------------------------------------------------+----------------------+ 
|                                                                |                      | 
+----------------------------------------------------------------+----------------------+ 
| Collins Stewart Europe Limited                                 |  [phone] | 
+----------------------------------------------------------------+----------------------+ 
| Adrian Hadden/ Adam Cowen                                      |                      | 
+----------------------------------------------------------------+----------------------+ 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RAGDGGGLVDFGLZM